Presentation is loading. Please wait.

Presentation is loading. Please wait.

Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab 

Published byHelmi Ranta Modified over 5 years ago

Similar presentations

Presentation on theme: "Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab "— Presentation transcript:

1 Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab  Tien Hoang, MD, Suzanne E. Dahlberg, PhD, Alan B. Sandler, MD, Julie R. Brahmer, MD, Joan H. Schiller, MD, David H. Johnson, MD  Journal of Thoracic Oncology  Volume 7, Issue 9, Pages (September 2012) DOI: /JTO.0b013e318260e106 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Prognostic nomograms predicting: (A) 1-year overall survival (OS); (B) 6-month progression-free survival (PFS). BM, bone marrow; BAC, bronchoalveolar carcinoma; LLN, lower limit of normal; PS, performance status; LDH, lactate dehydrogenase; ULN, upper limit of normal; BMI, body mass index. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318260e106) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Comparison of predicted survival with observed survival of quartile groups of patients in the validation set: (A) 1-year overall survival; (B) 6-month progression-free survival (PFS). The dotted line is the “ideal” line if there is a perfect match between predicted and observed survival. The vertical arrows represent 95% confidence intervals of observed survival. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318260e106) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Examples of the nomograms: (A) predicted 1-year overall survival (OS) of patient 1 who is a woman with large-cell lung cancer (P/S 30), ECOG PS 1 (P/S 35), BMI less than 18.5 (P/S 81), bone metastasis (P/S 29), and low serum albumin (P/S 32). Treated with PC alone (P/S 25), her total prognostic score is 232 points ( ). If bevacizumab is added to the doublet, her total prognostic score is 207 points ( ); (B) predicted 6-month PFS of patient 1. Treated with PC alone, her prognostic score is 112 points ( ). If bevacizumab is added to the doublet, her prognostic score is 75 points ( ); (C) predicted 1-year OS of patient 2 who is a woman with an adenocarcinoma of the lung with malignant effusion, otherwise having none of poor baseline factors. Treated with PC alone, her total prognostic score is 25 points. If bevacizumab is added to the doublet, her total prognostic score is 0; (D) predicted 6-month PFS of patient 2. Treated with PC alone, her prognostic score is 37 points. If bevacizumab is added to the doublet, her prognostic score is 0. BM, bone marrow; BAC, bronchoalveolar carcinoma; LLN, lower limit of normal; LDH, lactate dehydrogenase; ULN, upper limit of normal; PCB, PC and bevacizumab; PC, paclitaxel and carboplatin; BMI, body mass index; PFS, progression-free survival; ECOG, Eastern Cooperative Oncology Group. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318260e106) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab "

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network 

Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network 
PUBLISH ONLY Journal of Thoracic Oncology

PUBLISH ONLY Journal of Thoracic Oncology
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study  Thomas.

Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study  Thomas.
Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network 

Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network 
Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.
First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status  Young Joo Lee, MD, Heung Tae Kim, MD,

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status  Young Joo Lee, MD, Heung Tae Kim, MD,
John E. Pilling, FRCS (CTh), Michael E

John E. Pilling, FRCS (CTh), Michael E
Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer  Daniel Morgensztern, MD, Saiama.

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer  Daniel Morgensztern, MD, Saiama.
Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer  Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,

Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer  Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Similar presentations

Ads by Google